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Genome-wide association study identifies five susceptibility loci
for glioma
Abstract
To identify risk variants for glioma, we conducted a meta-analysis of two genome-wide association
studies by genotyping 550K tagging SNPs in a total of 1,878 cases and 3,670 controls, with validation in
three additional independent series totaling 2,545 cases and 2,953 controls. We identified five risk loci
for glioma at 5p15.33 (rs2736100, TERT; P = 1.50 x 10(-17)), 8q24.21 (rs4295627, CCDC26; P = 2.34
x 10(-18)), 9p21.3 (rs4977756, CDKN2A-CDKN2B; P = 7.24 x 10(-15)), 20q13.33 (rs6010620,
RTEL1; P = 2.52 x 10(-12)) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10(-8)). These data show that
common low-penetrance susceptibility alleles contribute to the risk of developing glioma and provide
insight into disease causation of this primary brain tumor.
Genome-wide association study identifies six susceptibility loci for glioma 
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To identify risk variants for glioma we conducted a meta-analysis of 2 genome-wide 
association studies, based on genotyping 550K tagging SNPs in a total of 1,878 cases 
and 3,670 controls, with validation in 3 additional independent series totaling 2,545 cases 
and 2,953 controls. We identified 6 risk loci for glioma at 5p15.33 (rs2736100, TERT; P = 
1.50 x 10-17), 8q24.21 (rs4295627, CCDC26; P = 2.34 x 10-18), 9p21.3 (rs4977756, 
CDKN2A/p14(ARF)/CDKN2B; P = 7.24 x 10-15), 20q13.33 (rs6010620, RTEL1; P = 2.52 x 10-
12), 11q13.4 (rs7124728; P = 8.18 x 10-9) and 11q23.3 (rs498872, PHLDB1; P = 1.07 x 10-8). 
These data show that common low-penetrance susceptibility alleles contribute to the risk 
of developing glioma and provide insight into disease causation of this primary brain 
tumor. 
 
 
Gliomas account for ~80% of primary malignant brain tumors with ~21,000 individuals being 
diagnosed with glioma each year in the US1. Most gliomas are associated with a dismal 
prognosis despite surgery, radiotherapy and chemotherapy1. To date no lifestyle exposures have 
been consistently linked to an increased risk of glioma except for ionizing radiation which is only 
responsible for a very small number of cases1. Evidence for an inherited predisposition to glioma 
is provided by the single gene disorders neurofibromatosis, tuberous sclerosis, retinoblastoma, 
Li-Fraumeni and Turcot’s syndromes .1  These syndromes are, however, rare and collectively only 
make a minor contribution to the 2-fold increased risk seen in first-degree relatives of patients 
with primary brain tumors (PBT)2. It is therefore likely that part of the familial risk is a 
consequence of the co-inheritance of multiple low-risk variants, some of which may be common 
and hence detectable through association analyses. Predicated on this hypothesis we have 
conducted 2 genome-wide association (GWA) studies to identify common variants influencing 
the risk of developing glioma. Pooling data from both GWA scans and following up the best-
supported associations in 3 independent case-control series has enabled us to identify 6 novel 
predisposition loci for glioma.  
 
The two GWA studies were conducted by centers in the UK and US; henceforth referred to as 
the UK-GWA and US-GWA studies respectively (Figure 1). In both GWA studies genotyping of 
cases was conducted using Illumina Infinium HD Human610-Quad BeadChips. 
 
The UK-GWA study was based on genotyping 636 glioma cases ascertained through the 
INTERPHONE Study3. After applying strict quality control criteria, genotype data were available 
for 631 cases (Figure 1). For controls we made use of publicly accessible Illumina Hap550K 
BeadChip genotype data generated on 1,438 individuals from the British 1958 Birth Cohort (58C, 
also known as the National Child Development Study)4, which included all live births in England, 
Wales and Scotland during a single week in 1958.  
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 The US-GWA study was based on genotyping 1,281 glioma cases ascertained through an 
ongoing collection being made by the MD Anderson Cancer Center. After applying strict quality 
control criteria, genotype data were available for 1,247 cases (Figure 1). For controls we made 
use of publicly accessible Illumina Hap550K BeadChip genotype data generated on 2,243 
individuals from the Cancer Genetic Markers of Susceptibility (CGEMS) studies of breast and 
prostate cancer5,6.  
 
Across both case series total of 572,571 SNPs were satisfactorily genotyped (99.4%), with mean 
individual sample call rates (the percentage of samples for which a genotype was obtained for 
each SNP) of 99.8%. We excluded 32 individuals because of non-Western European Ancestry 
and 2 because of cryptic relatedness (Figure 1; Supplementary Figure 1). 521,318 SNP 
genotypes were available on all 1,878 cases and 3,670 controls in the combined data. Prior to 
undertaking the meta-analysis we searched for potential errors and biases in the 2 GWA studies 
and imposed a high stringency for quality control for SNPs taken forward. Specifically, we 
considered only the 454,576 autosomal SNPs which had call rates >95% in all case and control 
series, which showed no extreme departure from Hardy-Weinberg equilibrium (HWE; P>10-5 in 
controls) and had minor allele frequencies (MAF) exceeding 1% in cases and controls (Figure 1).  
 
Comparison of the observed and expected distributions showed little evidence for an inflation of 
the test statistics in the 2 datasets (inflation factor7  = 1.02 and 1.05 for the UK-GWA and US-
GWA studies respectively based on the 90% least significant SNPs; Supplementary Figure 2), 
thereby excluding the possibility of significant hidden population substructure or differential 
genotype calling between cases and controls. Using data from both GWA studies we derived 
joint odds ratios (ORs) and confidence intervals under a fixed effects model for each SNP and 
associated P values from the standard normal distribution. The distribution of the association P 
values was significantly skewed from the null distribution; 34 of the SNPs having a P value<10-5, 
greater than the 4.5 conservatively expected under the null hypothesis (P <10-15, binomial test). 
 
To identify true risk alleles amongst these 34 SNPs, we conducted replication in 3 independent 
case-control series involving a total of 5,498 individuals that passed quality control filtering 
(French series, 1,392 cases and 1,602 controls; German series 504 cases and 573 controls; 
Swedish series, 649 cases and 778 controls). 31 of the 34 SNPs were satisfactorily genotyped in 
all 3 case-control series. On the basis of the combined analyses we found that signals from 15 of 
the 31 SNPs, representing 6 genomic regions, reached strong levels of evidence satisfying the 
generally accepted threshold for genome-wide statistical significance (i.e. P < 10-7; Table 1, 
Supplementary Table 1). For 3 SNPs, genotyping was not possible in at least one of the 3 series 
using the analytical platforms available within each study centre. In the French case-control 
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series SNPs rs9656979 and rs7257116 were not genotyped. An association between these 2 
SNPs and glioma risk was however not supported in either German or Swedish series 
(Supplementary Table 1). While rs7300686 was not typed in either the German or Swedish 
series an association with glioma risk was not supported in the French case-control series 
(Supplementary Table 1). Hence failure to genotype all additional case-control series for the 
three SNPs has not impacted on the study findings.  
 
Under a fixed-effects model the strongest signal was attained at rs4295627 (combined OR = 
1.36, 95% confidence interval [CI]: 1.29 - 1.43; P = 2.34 x 10-18) which localizes to 8q24.21 
(130754639 bps; Figure 2, Supplementary Figure 3, Table 1). There was, however evidence of 
between-study heterogeneity (Phet = 0.01) ascribable to the association being modest in the 
Swedish series. Under a random effects model, the combined OR was 1.36 (95% CI: 1.19-1.58; 
P = 2.01 x 10-5) using all case-control series data and 1.45 (95% CI: 1.32-1.57; P = 1.02 x 10-8) 
excluding the Swedish study. rs4295627 maps to intron 3 of CCDC26 (coiled-coil domain 
containing 26) a retinoic acid (RA) modulator of myeloid differentiation and death8. Retinoic acid 
induces caspase-8 transcription through phosphorylation of CREB and increases apoptotic 
responses to death stimuli in neuroblastoma cells9. Together with IFN-, RA induces 
differentiation, apoptotic death in glioblastoma cells with down regulation of telomerase activity10 
and it has been trialed as a chemotherapeutic agent11. There is some evidence to suggest a 
second 8q24.21 locus defined by rs891835, which maps to intron 1 of CCDC26 207kb telomeric 
to rs4295627 (130,560,934 bps; combined ORtrend = 1.24, 95% CI: 1.17–1.3; P = 7.54 x 10-11) 
and displays low LD between with rs4295627 (D’ and r2 = 0.59, 0.19 and 0.58, 0.26 in HapMap 
and GWA scan respectively). The OR for rs4295627 with adjustment for rs891835 was 1.30 
(95% CI: 1.20-1.41; P = 2.80 x 10-10).  Similarly, adjusting rs891835 for rs4295627 still provided 
evidence of an association, albeit only at a nominal level of significance (OR= 1.08, 95% CI: 
1.00-1.17; P = 0.03). There was also an increasing trend in OR with an increasing number of risk 
alleles (P = 2.67 x 10-13) and comparison of haplotype frequencies indicates that the prevalence 
of two distinct haplotypes differed between cases and controls (Supplementary Table 2). When 
we imputed 8q24.21 genotypes using genome-wide data rs1077236, mapping to 130709683bps, 
provided a marginally better association signal than rs4295627 in this dataset (P-values 2.75 x 
10-9 and 1.60 x 10-8 respectively; Supplementary Figure 4). Hence, the possibility remains that 
rs4295627 and rs891835, although only weakly associated with each other, are in LD with one 
or more causal variants in this region. 
 
The second strongest statistical evidence for an association was for rs2736100 (combined OR = 
0.79, 95% CI: 0.73 – 0.84; P = 1.50 x 10-17) mapping to 5p15.33 which localizes to intron 2 of 
TERT (1339516 bps; Figure 2, Supplementary Figure 3, Table 1). While this SNP is unlikely to 
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be directly causal, current knowledge implicates variation in TERT as the probable basis for the 
association signal. TERT is the reverse transcriptase component of telomerase, essential for 
telomerase activity in maintaining telomeres and is a critical to cell immortalization. While 
5p15.33 copy number change is not common in glioblastoma multiforme (GBM; Supplementary 
Figure 5) TERT expression has been shown to correlate with glioma grade and prognosis12. 
Several lines of evidence raise the possibility of a second locus defined by rs2853676 which also 
maps to intron 2 of TERT, 2kb telomeric to rs2736100 (1341547 bps; combined OR = 0.79, 95% 
CI: 0.76-0.83; P = 4.21 x 10-14) and is in weak LD with rs2736100 (D’ and r2 = 0.67, 0.15 and 
0.81, 0.24 in HapMap and GWA scan respectively). The OR for rs2736100 with adjustment for 
rs2853676 was 0.84 (95% CI: 0.79 - 0.89; P = 5.33 x 10-8) and similarly, adjusting rs2853676 for 
rs2736100 also provided evidence of an association, with little change in the risk estimate (OR= 
0.87, 95% CI: 0.81 – 0.93; P = 6.90 x 10-5). There was an increasing trend in OR with an 
increasing number of risk alleles (P = 1.19 x 10-19) and comparison of haplotype frequencies 
provided evidence of two distinct haplotypes differing between cases and controls 
(Supplementary Table 2). Recent data has implicated variation at 5p15.33 (TERT-CLMPTM1L) 
defined by rs2736098 with risk of multiple tumor types including lung and bladder cancer13. As 
LD between rs2736098 and both rs2736100 and rs2853676 is poor (D’ and r2 0.48, 0.11 and 
0.28, 0.02 in HapMap and GWA scan respectively) whether the 5p15.33 association with glioma 
has the same causal basis remains to be established.  
 
The third strongest statistical evidence for an association was for rs4977756 (combined OR = 
1.24, 95% CI: 1.19 - 1.30; P = 7.24 x 10-15), which maps 59kb telomeric to CDKN2B 
(22058652bps; Figure 2, Supplementary Figure 3, Table 1) within a 122kb region of LD at 
9p21.3. This region encompasses the CDKN2A/p14(ARF)/CDKN2B tumor suppressor genes. 
CDKN2A encodes p16(INK4A) a negative regulator of cyclin-dependant kinases and p14 (ARF1) 
an activator of p53. CDKN2A/p14(ARF)/CDKN2B has an established role in glioma with 
mutations in CDKN2A reported to be detectable in ~50% of tumors14,15 and loss of expression 
linked to poor prognosis12. Furthermore, germline mutation of the locus, specifically p14ARF has 
been reported to cause the melanoma-astrocytoma syndrome16,17. Regulation of p16/p14ARF 
has been observed to be important for sensitivity to ionizing radiation, the only environmental 
factor strongly linked to gliomagenesis18. While rs4977756 is unlikely to be directly causal these 
data provide evidence that common variation in addition to rare mutations in this region is a 
basis of glioma predisposition.  
 
The fourth strongest statistical evidence for an association was for rs6010620 (combined OR = 
1.28, 95% CI: 1.21 – 1.35; P = 2.52 x 10-12) which localizes to intron 12 (61780283 bps) of the 
RAD3-like helicase RTEL1 (regulator of telomere elongation helicase 1)19 and maps within a 
65kb region of LD at 20q13.33 (Figure 2, Supplementary Figure 3, Table 1). Amplification of 
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20q13.33 encompassing RTEL1 is seen in ~30% of glioma. While copy number change 
correlates with RTEL1 mRNA expression levels a similar relationship is seen with other genes 
mapping to the region (Supplementary Figure 5). RTEL1 has recently been shown to maintain 
genomic stability directly by suppressing homologous recombination19. These data coupled with 
the established role of TERT in glioma biology makes RTEL1 an attractive candidate for the 
association signal at 20q13.33. Alternatively, the 20q13.33 association may be mediated through 
variation in other genes mapping to the region of LD, such as TNFRSF6B (alias DcR3) whose 
expression in gliomas has been correlated with tumor grade20,21. TNFRSF6B is thought to play a 
regulatory role in suppressing FasL- and LIGHT-mediated cell death and acts as a decoy 
receptor competing with death receptors for ligand binding and hence immune evasion of 
gliomas20,21. 
 
The fifth strongest statistical evidence for an association was for rs7124728 (combined OR = 
1.18, 95% CI: 1.13–1.24; P = 8.18 x 10-9). rs7124728 maps within a 92kb region of LD at 
11q13.4 (70554083 bps; Figure 2, Supplementary Figure 3, Table 1), a region bereft of genes or 
predicted transcripts. Furthermore, there are no protein-coding transcripts or predicted 
genes/microRNAs in the vicinity of the marker (i.e. 300kb flanking sequence). 
 
The sixth strongest signal was at rs498872 (combined OR = 1.18, 95% CI: 1.13 – 1.24; P = 1.07 
x 10-8) which maps to the 5’ UTR of PHLDB1 (pleckstrin homology-like domain, family B, 
member 1 protein; alias LL5) within a large LD block of 101kb on 11q23.3 (117982577bps; 
Figure 2, Supplementary Figure 3, Table 1). There was some evidence of between-study 
heterogeneity (Phet = 0.04) ascribable no association detectable in the German series. Under a 
random effects model, the combined OR was 1.16 (95% CI: 1.05-1.28; P = 2.24 x 10-3) for all 
studies and 1.22 (95% CI: 1.16-1.28; P = 2.56 x 10-10, Phet= 0.40) excluding the German series. 
Although there is no direct evidence for a role of PHLDB1 or other genes mapping to the region 
of LD at 11q23.3 (e.g. MLL, ARCN1, TREH) this genomic region is deleted in ~14% of gliomas 
(Supplementary Figure 5) and commonly deleted in neuroblastoma22.   
 
Given biological differences between the histological forms of glioma23, we have sought to 
analyze the association between SNP genotypes and risk of  tumors of glial origin, GBM and 
astrocytic linage through case-only logistic regression. Accepting the limitations of pooling data 
without central histopathological review, there was evidence that GBMs may have a different risk 
profile notably with respect to rs4295627 (CCDC26), rs498872 (PHLDB1) and rs2736100 
(TERT) (Supplementary Table 3). Due to significant between study heterogeneity we cannot 
however exclude the possibility that the impact of variants on risk is generic in nature and is not 
directed to influencing the risk of developing a specific histological form of glioma.  
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When we modeled pairwise combinations of all of the SNPs we only found evidence of 
interactive effects between 8q24.21 SNPs (Supplementary Table 4). For all other pairwise 
combinations each locus had an independent role in glioma development (P interaction >0.10). The 
risk of glioma increases with increasing numbers of variant alleles for the 6 loci (ORper-allele=1.24, 
95% CI: 1.21-1.28; P = 1.30 x 10-61; Supplementary Table 5). The proportion of case and control 
subjects grouped according to the number of risk alleles is shown in Figure 3. The distribution of 
risk alleles follows a normal distribution in both case and controls, with a shift towards a higher 
number of risk alleles in cases. Figure 3 also shows the ORs relative to the median number of 5 
risk alleles. Individuals with 10+ risk alleles have at least a 3-fold increase in risk of developing 
glioma compared to those with a median number of risk alleles. These ORs may be slight 
underestimates because the additive model imposed for allele counting assumes equal 
weighting across all SNPs. We estimate the 6 loci we have identified to date through our GWA 
account for ~10% of the excess familial risk of glioma (assuming both naïve multiplicative or 
additive models). It is acknowledged, however, that the present data provide only crude 
estimates of the overall effect on susceptibility attributable to variation at the 6 loci as the effect 
of the actual common causal variant responsible for the association, once identified, will typically 
be larger. Furthermore, many of the loci may carry additional causal variants, potentially 
including low-frequency variants with larger influence on glioma risk.  
 
While fine-mapping and resequencing is required to identify the specific variants underlying each 
of the 6 associations so far identified, we conducted 2 analyses to investigate the potential basis 
of causality. We interrogated HapMap to identify non-synonymous SNPs (nsSNPs) highly 
correlated with the most strongly associated SNP within each region of association. The 
strongest LD was between rs6010620 and nsSNP rs3848668 (D’ = 1.0, r2 = 0.05; Supplementary 
Table 6). Accepting the caveat that HapMap is not comprehensive these data suggest the 
associations identified so far are most probably mediated through LD with sequence changes 
that influence gene expression rather than protein sequence or through LD with low frequency 
variants (i.e. variants with MAF of 0.001-0.01) that are not catalogued by HapMap. To explore 
whether any of the associations reflect cis-acting regulatory effects on a nearby gene, we 
searched for genotype–expression correlations in lymphoblastoid cell lines24,25, and in normal 
brain tissue26 using publicly available data. We did not, however, find any significant relationship 
between any of the SNP genotypes and gene expression (Supplementary Figure 6). These 
findings do not exclude subtle effects on gene expression or possibly that the variants exert 
effects through untested transactivation of genes.   
 
These results provide the first unambiguous evidence that common genetic variation influences 
the risk of developing glioma. Our findings also provide insight into the biological basis of 
predisposition. They highlight the importance of variation in genes encoding components of 
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CDKN2A-CDK4 signaling pathway in the development of glioma. Moreover this pathway, 
elucidated through the extended interaction network of CDKN2A, incorporates TERT (through 
mutual interaction with HSP90) and other genes (including CCDC26) we have identified as risk 
factors for glioma. The identification of additional variants associated with glioma predisposition 
should refine the allelic architecture of disease susceptibility and potentially provide further 
insights into the biology of this PBT. 
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METHODS 
 
Subjects 
 
UK- GWA study 
The UK study was based on 636 cases (401 male, 285 female; mean age at diagnosis 46 years; 
SD 12) ascertained through the INTERPHONE Study3. Briefly, the INTERPHONE Study was an 
international multi-centre case-control study of primary brain tumors coordinated by the 
International Agency for Research on Cancer (IARC), with material collected between 
September 2000 and February 2004. UK patients with PBT were collected through 
neurosurgery, neuropathology, oncology, and neurology centers in the Thames regions of 
Southeast England and the Northern UK including central Scotland, the West Midlands, West 
Yorkshire, and the Trent area. Cases were patients with glioma [International Classification of 
Diseases (ICD), 10th revision, code C71; International Classification of Diseases for oncology 
(ICD-O), 2nd ed., codes 9380-9384, 9390-9411, 9420-9451, and 9505]. Cases with previous 
brain tumors were excluded.  To minimize population stratification cases with self reported non-
UK ancestry were excluded from the present study. Individuals from the 1958 Birth Cohort 
served as source of controls4.  
                                                                                                                                                                               
US-GWA study 
The US study was based on 1,247 cases (768 male, 479 female; mean age at diagnosis 47 
years; SD 13) ascertained through the MD Anderson Cancer Center, Texas, between 1990 and 
2008. Cases were patients with glioma (ICD10 code C71; ICD-O codes 9380-9384, 9390-9411, 
9420-9451, and 9505). Individuals from CGEMS5,6 served as controls.  
 
Replication series 
 
French Glioma Collection (FGC): systematic series of 1,439 patients with histologically proven 
glioma (WHO classification AIII, AI, AIII, OII, OIII, OAII, OAII, OAIII, GBM-IV) ascertained 
through the Service de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière Paris. The 
controls are taken from the SU.VI.MAX (SUpplementation en VItamines et 
MinrauxAntioXydants) study of 12,735 healthy subjects (women aged 35 to 60 years; men aged 
45 to 60 years) recruited from across France in 199427. 
 
Swedish Glioma Collection (SGCCS): 215 glioma cases ascertained as part of the 
INTERPHONE Study3 conducted between 2000 and 2002 in Sweden, 134 cases from Umeå 
University Hospital, 122 from the Northern Sweden Health and Disease Study (NSHDS)28 and 
203 from neurosurgery university clinics in Sweden. 383 controls for the INTERPHONE study 
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were randomly selected from the population register, frequency matched to brain tumor cases 
on age, sex, and geographical region. In addition 400 controls were ascertained from NSHDS 
that were age, gender and geographically representative of the cohort. 
 
German Glioma Collection (GGC): 564 patients who underwent surgery for a glioma at the 
Department of Neurosurgery, University of Bonn Medical Center, between 1996 and 2008. All 
histological diagnoses were made at the Institute for Neuropathology/German Brain Tumor 
Reference Center, University of Bonn Medical Center. Control subjects were 576 healthy 
individuals (288 men, 288 women; mean age 31, range 18-45) of German origin recruited in 
2004 by the Institute of Transfusion Medicine and Immunology, Mannheim.  
 
Ethics 
Collection of blood samples and clinico-pathological information from patients and controls was 
undertaken with informed consent and relevant ethical review board approval in accordance with 
the tenets of the Declaration of Helsinki. 
 
Genotyping 
DNA was extracted from samples using conventional methodologies and quantified using 
PicoGreen (Invitrogen, Carlsbad, USA). A genome-wide scan of tag SNPs was conducted using 
the Illumina Infinium HD Human610-Quad BeadChips according to the manufacturer's protocols 
(Illumina, San Diego, USA; Supplementary Methods). DNA samples with GenCall scores <0.25 
at any locus were considered “no calls”.  A DNA sample was deemed to have failed if it 
generated genotypes at <95% of loci. A SNP was deemed to have failed if fewer than 95% of 
DNA samples generated a genotype at the locus. To ensure quality of genotyping, a series of 
duplicate samples were genotyped in the same batches.   
 
Subsequent genotyping of SNPs was conducted using either competitive allele-specific PCR 
KASPar chemistry (KBiosciences Ltd, Hertfordshire, UK) or single-base primer extension 
chemistry MALDI-TOF MS detection (Sequenom, San Diego, USA). All primers and probes used 
are available on request. Genotyping quality control was further evaluated through inclusion of 
duplicate DNA samples in SNP assays. For all SNP assays >99% concordant results were 
obtained.  Samples having SNP call rates <90% were excluded from the analysis.  
 
 
Statistical analysis 
 
Statistical analyses were undertaken using R (v2.6), STATA (version 8; State College, Texas, 
US) and PLINK (version 1.05)29 software. Genotype data were used to search for duplicates and 
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closely related individuals amongst all samples in each of the GWA studies. Identity by state 
(IBS) values were calculated for each pair of individuals, and for any pair with allele sharing of 
>80%, the sample generating the lowest call rate was removed from further analysis. To identify 
individuals who might have non-Western European ancestry, we merged our case and control 
data with the 60 western European (CEU), 60 Nigerian (YRI), and 90 Japanese (JPT) and 90 
Han Chinese (CHB) individuals from the International HapMap Project. For each pair of 
individuals we calculated genome-wide IBS distances, on markers shared between HapMap and 
our SNP panel, and used these as dissimilarity measures upon which to perform principal 
component analysis. The first two principal components for each individual were plotted and any 
individual not present in the main CEU cluster (i.e. outside 5% from cluster centroids) was 
excluded from subsequent analyses.  
 
In the UK-GWA study, genotyped samples were excluded from analyses for the following 
reasons: relatedness (n=0) and non-CEU ancestry (n=3). In the US-GWA study, genotyped 
samples were excluded from analyses for the following reasons: relatedness (n=2) and non-CEU 
ancestry (n=23). 
 
The adequacy of the case-control matching and possibility of differential genotyping of cases 
and controls were formally evaluated using Q-Q plots of test statistics. Deviation of the genotype 
frequencies in the controls from those expected under Hardy-Weinberg Equilibrium (HWE) was 
assessed by a 2 test, or Fisher’s exact test where an expected cell count was <5. 
 
The association between each SNP and risk of glioma was assessed by the Cochran-Armitage 
trend test. Odds ratios and associated 95% CIs were calculated by unconditional logistic 
regression. Relationships between multiple SNPs showing association with glioma risk in the 
same region were investigated using logistic regression analysis, and the impact of additional 
SNPs from the same region was assessed by a likelihood-ratio test.  
 
The combined effect of each pair of risk locus was investigated by logistic regression modeling 
with evidence for interactive effects between SNPs assessed by a likelihood ratio test. The OR 
and trend test for increasing numbers of deleterious alleles was estimated by counting two for a 
homozygote and one for a heterozygote.  
 
Meta-analysis was conducted using standard methods based on weighted average of study-
specific estimates of the ORs, using inverse variance weights. Cochran’s Q statistic to test for 
heterogeneity and the I2 statistic to quantify the proportion of the total variation due to 
heterogeneity were calculated. The sibling relative risk attributable to a given SNP was 
calculated using the formula: 
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where p is the population frequency of the minor allele, q=1-p, and r  and r  are the relative risks 
(estimated as OR) for heterozygotes and rare homozygotes, relative to common homozygotes. 
Assuming a multiplicative interaction the proportion of the familial risk attributable to a SNP was 
calculated as log( )/log( ), where  is the overall familial relative risk estimated from 
epidemiological studies, assumed to be 2.1 .
1 2
*
0 0 
2  A naïve estimation of the contribution of all of the 
loci identified to the excess familial risk of glioma under an additive model was calculated using 
the formula:  
 
 
Bioinformatics 
LD metrics between SNPs reported in HapMap were based on Data Release 2/phase III Feb09 
on NCBI B35 assembly, dbSNPb125, except for between rs2736098 and rs2736100 and 
rs2853676 which were only available in Data Release 23a/phase II March08.   
 
We used Haploview software (v3.2) to infer the LD structure of the genome in the regions 
containing loci associated with disease risk. Prediction of the un-typed SNP in the case–control 
data sets of GWA data was carried out using IMPUTE and SNPTEST on HapMap (HapMap 
Data Rel 2/phase III Feb09 on NCBI B35 assembly, dbSNPb125).  
 
To examine for a relationship between SNP genotype and mRNA expression in lymphocytes 
and normal human cortex we used publicly available data. 90 Caucasian derived Epstein-Barr 
virus–transformed lymphoblastoid cell lines were analyzed using Sentrix Human-6 Expression 
BeadChips (Illumina, San Diego, USA). Online recovery of data was performed using 
WGAViewer Version 1.25 Software24,25. 193 normal human cortex cells were analyzed using 
Illumina HumanRef-seq-8 Expression BeadChip arrays26. Where SNPs genotyped in our study 
had not been typed HAPMAP data were used to identify correlated SNPs in high LD (r2 >0.8). 
Differences in the distribution of levels of mRNA expression between SNP genotypes were 
compared using a Wilcoxon-type test for trend. Relationship between copy number change and 
mRNA expression at loci in glioma was investigated using data from The Cancer Genome Atlas 
(TCGA) 14. The Bioconductor module CGHcall was used to assign copy number status.  
 
We searched for interactions between proteins encoded by genes mapping to association 
signals using the program PINA30.  
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URLs 
 
The R suite can be found at http://www.r-project.org/ 
Bioconductor: http://www.bioconductor.org/ 
Detailed information on the tag SNP panel can be found at http://www.illumina.com/ 
dbSNP: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=snp 
HAPMAP: http://www.hapmap.org/ 
http://pipeline.lbl.gov/cgi-bin/gateway2 
KBioscience: http://kbioscience.co.uk/ 
WGAViewer: http://www.genome.duke.edu/centers/pg2/downloads/wgaviewer.php 
1958 Birth Cohort: http://www.cls.ioe.ac.uk/studies.asp?section=000100020003 
PLINK: http://pngu.mgh.harvard.edu/~purcell/plink/ 
Cancer Genetic Markers of Susceptibility (CGEMS): http://cgems.cancer.gov/ 
The Cancer Genomics Data Portal: http://cbio.mskcc.org/cancergenomics-dataportal 
The Cancer Genome Atlas (TCGA) data portal: http://tcga-data.nci.nih.gov/tcga/homepage.htm  
A Survey of Genetic Human Cortical Gene Expression: http://labs.med.miami.edu/myers/ 
IMPUTE: http://www.stats.ox.ac.uk/~marchini/software/gwas/impute.html  
SNPTEST: http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html  
PINA (Protein Interaction Network Analysis platform): http://csbi.ltdk.helsinki.fi/pina/ 
 
 
Note: Supplementary information is available on the Nature Genetics website 
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Table 1: Summary of results for glioma SNPs replicated. Gene(s) mapping within 20kb of each SNP are detailed 
 
GWA studies Replication studies Combined 
SNP Chr Gene 
Location 
(bp) 
Ancestral 
allele 
frequency 
Ancestral 
allele 
Non-
ancestral 
allele 
OR  
(95% CI) P  
OR 
(95% CI) P  
OR  
(95% CI) P  P het 
rs2736100 5 TERT 1,339,516 0.51 T G 
0.83 
 (0.75-0.91) 2.21E-06 
0.75  
(0.67-0.83) 2.87E-13 
0.79  
(0.73-0.84) 1.50E-17 0.18 
rs2853676 5 TERT 1,341,547 0.27 G A 
1.22  
(1.14-1.31) 5.30E-06 
1.3 (1.21-
1.38) 1.06E-09 
1.26  
(1.2-1.32) 4.21E-14 0.67 
rs10464870 8 CCDC26 130,547,005 0.21 T C 
1.24  
(1.15-1.34) 3.90E-06 
1.22  
(1.13-1.31) 1.77E-05 
1.23  
(1.17-1.3) 3.04E-10 0.05 
rs891835 8 CCDC26 130,560,934 0.22 T G 
1.24  
(1.15-1.33) 3.92E-06 
1.24  
(1.15-1.33) 4.43E-06 
1.24  
(1.17-1.3) 7.54E-11 0.01 
rs6470745 8 CCDC26 130,711,103 0.20 A G 
1.3  
(1.2-1.39) 5.79E-08 
1.31  
(1.22-1.41) 9.09E-09 
1.3  
(1.24-1.37) 2.77E-15 0.01 
rs16904140 8 CCDC26 130,734,825 0.21 G A 
1.25 
(1.16-1.35) 1.41E-06 
1.28  
(1.19-1.37) 1.14E-07 
1.27  
(1.2-1.33) 7.88E-13 0.01 
rs4295627 8 CCDC26 130,754,639 0.17 T G 
1.33  
(1.23-1.42) 1.47E-08 
1.39  
(1.3-1.49) 2.20E-11 
1.36  
(1.29-1.43) 2.34E-18 0.01 
rs1063192 9 CDKN2A/B 21,993,367 0.44 T C 
1.21  
(1.13-1.29) 1.44E-06 
1.21  
(1.14-1.29) 6.97E-07 
1.21  
(1.16-1.27) 4.61E-12 0.81 
rs2157719 9 CDKN2A/B 22,023,366 0.57 G A 
0.82  
(0.74-0.9) 6.80E-07 
0.82  
(0.75-0.9) 4.42E-07 
0.82  
(0.77-0.88) 1.41E-12 0.68 
rs1412829 9 CDKN2A/B 22,033,926 0.42 T C 
1.22  
(1.14-1.3) 7.23E-07 
1.23  
(1.15-1.3) 1.80E-07 
1.22  
(1.17-1.28) 6.23E-13 0.67 
rs4977756 9 CDKN2A/B 22,058,652 0.40 A G 
1.25  
(1.17-1.32) 2.39E-08 
1.24  
(1.16-1.31) 5.90E-08 
1.24  
(1.19-1.3) 7.24E-15 0.94 
rs7124728 11   70,554,083 0.44 C T 
1.38  
(1.3-1.47) 2.28E-13 
1.05  
(0.97-1.13) 2.24E-01 
1.18  
(1.13-1.24) 8.18E-09 0.01 
rs498872 11 PHLDB1 117,982,577 0.31 C T 
1.26  
(1.17-1.34) 1.03E-07 
1.12  
(1.04-1.2) 4.56E-03 
1.18  
(1.13-1.24) 1.07E-08 0.04 
rs6010620 20 RTEL1 61,780,283 0.23 G A 
1.28  
(1.18-1.38) 8.38E-07 
1.28  
(1.18-1.38) 6.49E-07 
1.28  
(1.21-1.35) 2.52E-12 0.38 
rs2297440 20 RTEL1 61,782,743 0.22 C T 
1.28  
(1.18-1.38) 1.01E-06 
1.26  
(1.16-1.35) 4.44E-06 
1.27  
(1.2-1.34) 2.06E-11 0.40 
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521,318 SNPs common across all case and control series
Meta-analysis of 454,576 SNPs 
UK-GWA study: 631 cases and 1434 controls
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Figure 1: Patient and single SNP exclusion schema for genome-wide studies
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Figure 2:  LD structure and association results for the 6 confirmed glioma disease-
associated regions: (a) 8q24.21; (b) 5p15.33; (c) 9p21.3; (d) 20q13.33; (e) 11q23.3; and 
(f) 11q13.4. Chromosomal positions based on NCBI build 36 coordinates, showing 
Ensemble (release 48) genes. Armitage trend test P values (as –log10 values; left y axis) 
are shown for SNPs analysed in the GWA-studies in blue and for the combined analysis 
including the replication series in red. Recombination rates in HapMap CEU across the 
region are shown in black (right y axis). Also shown are the relative positions of genes 
mapping to each region of association. Exons of genes have been redrawn to show the 
relative positions in the gene, therefore maps are not to physical scale.
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Figure 3: (a) Distribution of risk alleles in glioma cases (blue bars) and controls (green bars); (b) Plot of the increasing 
ORs for glioma with increasing number of risk alleles. The ORs are relative to the median number of five risk alleles; Vertical 
bars correspond to 95% confidence intervals.
OR 95% CI P
rs2736100 5 230 TT 645 TG 372 GG 546 TT 1103 TG 584 GG 0.82 0.72-2.78 1.01E-04
rs2853676 5 109 AA 568 AG 570 GG 149 AA 894 AG 1191 GG 1.28 1.17-3.24 1.35E-05
rs10464870 8 683 TT 488 TC 76 CC 1370 TT 761 TC 101 CC 1.26 1.14-3.22 9.62E-05
rs891835 8 661 TT 498 TG 88 GG 1344 TT 773 TG 115 GG 1.28 1.16-3.24 2.16E-05
rs6470745 8 699 AA 469 AG 79 GG 1415 AA 730 AG 90 GG 1.32 1.2-3.28 4.20E-06
rs16904140 8 85 AA 476 AG 686 GG 110 AA 773 AG 1352 GG 1.22 1.11-3.18 5.29E-04
rs4295627 8 735 TT 451 TG 60 GG 1496 TT 667 TG 72 GG 1.35 1.22-3.31 1.68E-06
rs1063192 9 326 TT 602 TC 319 CC 700 TT 1092 TC 436 CC 1.25 1.15-3.21 7.62E-06
rs2157719 9 335 AA 601 AG 311 GG 726 AA 1078 AG 428 GG 0.80 0.7-2.76 6.15E-06
rs1412829 9 347 TT 596 TC 302 CC 749 TT 1072 TC 412 CC 1.25 1.16-3.21 5.59E-06
rs4977756 9 377 AA 594 AG 276 GG 782 AA 1083 AG 370 GG 1.23 1.13-3.19 3.46E-05
rs7124728 11 76 TT 740 TC 431 CC 424 TT 1145 TC 663 CC 1.53 1.42-3.49 2.56E-14
rs498872 11 156 TT 589 TC 502 CC 211 TT 954 TC 1070 CC 1.27 1.17-3.23 5.07E-06
rs6010620 20 46 AA 405 AG 796 GG 123 AA 785 AG 1327 GG 1.20 1.08-3.16 0.0025
rs2297440 20 45 TT 397 TC 804 CC 119 TT 777 TC 1330 CC 1.22 1.09-3.18 0.0016
rs7300686 12 307 TT 454 TC 466 CC 586 TT 1074 TC 508 CC 1.36 1.26-3.32 4.72E-10
rs17748 11 84 TT 487 TC 675 CC 119 TT 753 TC 1363 CC 1.25 1.14-3.21 1.23E-04
rs9656979 8 351 TT 630 TC 266 CC 742 TT 1098 TC 393 CC 1.20 1.1-3.16 3.65E-04
rs9369226 6 57 AA 428 AG 762 GG 73 AA 659 AG 1502 GG 0.79 0.67-2.75 1.73E-04
rs171125 16 19 AA 249 AG 978 GG 6 AA 359 AG 1838 GG 1.43 1.26-3.39 2.33E-05
rs6931798 6 56 TT 426 TC 765 CC 71 TT 656 TC 1500 CC 1.26 1.14-3.22 2.11E-04
rs6869535 5 28 AA 307 AG 912 GG 69 AA 682 AG 1483 GG 1.32 1.19-3.28 5.17E-05
rs2110922 2 188 TT 579 TG 478 GG 273 TT 980 TG 957 GG 0.85 0.75-2.81 0.0016
rs2072532 2 390 TT 606 TC 251 CC 572 TT 1128 TC 533 CC 1.21 1.11-3.17 1.71E-04
rs7257116 19 148 TT 581 TC 518 CC 339 TT 1095 TC 796 CC 1.22 1.12-3.18 1.36E-04
rs1509937 10 517 AA 552 AG 178 GG 997 AA 995 AG 243 GG 1.15 1.05-3.11 0.0062
rs2206920 20 18 AA 239 AG 990 GG 18 AA 342 AG 1850 GG 1.32 1.16-3.28 8.44E-04
rs12531711 7 966 AA 262 AG 19 GG 1807 AA 407 AG 20 GG 1.23 1.08-3.19 0.0089
rs10488631 7 965 TT 263 TC 19 CC 1810 TT 405 TC 20 CC 1.24 1.09-3.2 0.0063
rs10924559 1 29 AA 324 AG 872 GG 52 AA 460 AG 1699 GG 0.80 0.66-2.76 0.0014
rs1384847 4 0 AA 170 AG 1077 GG 28 AA 360 AG 1847 GG 1.40 1.21-3.36 3.85E-04
rs1941114 18 18 AA 268 AG 961 GG 60 AA 602 AG 1573 GG 0.72 0.58-2.68 8.90E-06
rs7325443 13 50 TT 427 TC 770 CC 73 TT 633 TC 1529 CC 1.27 1.15-3.23 1.54E-04
rs7325927 13 129 TT 456 TC 659 CC 147 TT 807 TC 1281 CC 0.82 0.71-2.78 3.27E-04
Supplementary Table 1: Genotypes for the 34 SNPs in cases and controls in each of the case-control series. Also shown are Odds ratios and
associated 95% confidence intervals, for each of the SNPs genotyped. 
ChrSNP
ResultsCase genotypes Control genotypes
rs2736100 rs2853676 Cases Controls OR 95% CI P
TT GG 678 1'414 1.00 Reference
TT GA 91 164 1.13 (0.86 - 1.49) 0.37
TT AA 3 8 0.93 (0.24 - 3.53) 0.91
TG GG 975 1'521 1.33 (1.18 - 1.5) 5.36E-06
TG GA 1'158 1'569 1.53 (1.36 - 1.73) 3.17E-12
TG AA 60 73 1.67 (1.17 - 2.39) 0.005
GG GG 310 449 1.45 (1.22 - 1.72) 2.67E-05
GG GA 654 842 1.64 (1.43 - 1.88) 2.75E-12
GG AA 372 390 1.97 (1.66 - 2.33) 7.77E-15
Per risk allele 1.08 (1.06-1.09) 1.19E-19
P interaction 0.308
rs4295627 rs891835 Cases Controls OR 95% CI P
TT TT 3'349 2'044 1.00 Reference
TT TG 951 573 1.02 (0.90 - 1.15) 0.76
TT GG 82 44 0.90 (0.62 - 1.30) 0.58
TG TT 538 384 1.19 (1.03 - 1.38) 0.02
TG TG 1'144 946 1.40 (1.25 - 1.54) 4.66E-10
TG GG 141 145 1.73 (1.36 - 2.20) 7.82E-06
GG TT 16 17 1.89 (0.95 - 3.78) 0.07
GG TG 91 82 1.48 (1.09 - 2.01) 0.01
GG GG 84 116 2.35 (1.76 - 3.14) 7.04E-09
Per risk allele 1.08 (1.07-1.11) 2.47E-19
P interaction 0.03
Supplementary Table 2: Risk of glioma by combined genotypes for rs2736100-rs285
Haplotype* Case Frequency
Control 
Frequency P
TG 0.409 0.467 4.23E-17
GA 0.296 0.247 5.1E-16
GG 0.269 0.26 0.1439
TA 0.026 0.026 0.733
*Haplotype consists of rs2736100 and rs2853676
Haplotype* Case Frequency
Control 
Frequency P
TTATGT 0.424 0.462 2.00E-04
TTACGT 0.202 0.198 0.6561
CGGCAG 0.143 0.099 7.46E-12
CGATGT 0.087 0.094 0.2041
TTGCAG 0.062 0.059 0.6354
TGGCAG 0.02 0.02 0.9459
TTGCAT 0.016 0.02 0.1366
TTACAT 0.015 0.017 0.4222
CTATGT 0.011 0.011 0.9447
*Haplotype consists of rs10464870, rs891835, rs6470745,
rs9656979, rs16904140 and rs4295627
53676 and rs4295627-rs891835. 
SNP Comparison P Between study P
rs4295627 Glial vs GBM 2.52E-09 0.111
Astrocytic vs GBM 5.12E-05 0.013
Glial vs astrocytic 0.026 0.016
Glial & astrocytic vs GBM 3.80E-08 0.014
rs498872 Glial vs GBM 0.009 0.748
Astrocytic vs GBM 0.030 0.145
Glial vs astrocytic 0.158 0.406
Glial & astrocytic vs GBM 0.005 0.999
rs4977756 Glial vs GBM 0.230 9.60E-05
Astrocytic vs GBM 0.0008 0.003
Glial vs astrocytic 0.411 0.121
Glial & astrocytic vs GBM 0.010 0.001
rs2736100 Glial vs GBM 3.30E-04 0.069
Astrocytic vs GBM 1.91E-04 0.068
Glial vs astrocytic 0.548 0.172
Glial & astrocytic vs GBM 2.55E-05 0.047
rs6010620 Glial vs GBM 0.003 0.429
Astrocytic vs GBM 0.138 0.126
Glial vs astrocytic 0.070 0.003
Glial & astrocytic vs GBM 0.016 0.043
rs7124728 Glial vs GBM 0.030 3.60E-06
Astrocytic vs GBM 0.411 5.00E-08
Glial vs astrocytic 0.203 1.00E-06
Glial & astrocytic vs GBM 0.153 3.60E-10
Supplementary Table 3: Clinico-pathological association testing.Tumors of glial 
origin defined by ICD-O codes 93803, 94423, 94503, 94513, GBM  by ICD-O codes 
94401-13, and astrocytic tumors by ICD-O codes 94003-245. 
TERT 11q13.4 PHLDB1
rs2853676 rs10464870 rs891835 rs6470745 rs16904140 rs4295627 rs1063192 rs2157719 rs1412829 rs4977756 rs7124728 rs498872 rs6010620 rs2297440
rs2736100
0.31 
(10,731)
0.68 
(10,800)
0.73 
(10,667)
0.74 
(10,850)
0.30 
(10,836)
0.30 
(10,846)
0.34 
(10,774)
0.20 
(10,825)
0.41 
(10,810)
0.27 
(10,811)
0.19 
(10.725)
0.55 
(10,825)
0.60 
(10,763)
0.63 
(10,623)
rs2853676
0.26 
(10,758)
0.78 
(10,629)
0.38 
(10,808)
0.41 
(10.798)
0.41 
(10,803)
0.74 
(10,739)
0.85 
(10,782)
0.97 
(10,777)
0.40 
(10,765)
0.56 
(10,703)
0.20 
(10,783)
0.66 
(10,728)
0.56 
(10,598)
rs10464870
0.62 
(10,705)
5.57x10-5 
(10,887)
3.92x10-12 
(10,880)
0.02 
(10,880)
0.86 
(10,813)
0.80 
(10,865)
0.55 
(10,848)
0.73 
(10,848)
0.73 
(10,765)
0.18 
(10,860)
0.94 
(10,797)
0.86 
(10,661)
rs891835
1.56x10-4 
(10,753)
1.45x10-4 
(10.740)
0.03 
(10,747)
0.77 
(10,677)
0.71 
(10,728)
0.53 
(10,713)
0.67 
(10,711)
0.55 
(10,625)
0.24 
(10,729)
0.33 
(10,668)
0.22 
(10,572)
rs6470745
0.33 
(10,926)
0.48 
(10,933)
0.17 
(10,861)
0.19 
(10,911)
0.51 
(10,900)
0.33 
(10,898)
0.36 
(10,806)
0.39 
(10,912)
0.73 
(10,846)
0.61 
(10,711)
rs16904140
0.26 
(10,923)
0.41 
(10,852)
0.49 
(10,898)
0.96 
(10,888)
0.50 
(10,884)
0.41 
(10,798)
0.41 
(10,903)
0.89 
(10,836)
0.78 
(10,703)
rs4295627
0.38 
(10,859)
0.39 
(10,911)
0.82 
(10,896)
0.49 
(10,894)
0.55 
(10,806)
0.44 
(10,909)
0.75 
(10,846)
0.73 
(10,708)
rs1063192
0.60 
(10,838)
0.58 
(10,827)
0.76 
(10,831)
0.14 
(10,736)
0.73 
(10,839)
0.87 
(10,772)
0.97 
(10,636)
rs2157719
0.54 
(10,874)
0.54 
(10,874)
0.23 
(10,789)
0.70 
(10,889)
0.80 
(10,823)
0.87 
(10,687)
rs1412829
0.59 
(10,857)
0.26 
(10,771)
0.44 
(10,873)
0.60 
(10,814)
0.65 
(10,674)
rs4977756
0.12 
(10,777)
0.29 
(10,869)
0.70 
(10,808)
0.84 
(10,670)
11q13.4 rs7124728
0.29 
(10,869)
0.25 
(10,720)
0.22 
(10,588)
PHLDB1 rs498872
0.19 
(10,820)
0.12 
(10,690)
RTEL1 rs6010620
0.28 
(10,632)
Supplementary Table 4: Pairwise analysis of all SNPs associated with glioma risk. For each row-column combination, numbers show the P value for
inclusion of an interaction term between the two SNPs. Numbers in parentheses are the number of samples from which statistics are calculated. 
CDKN2A/B
RTEL1CCDC26
TERT
CCDC26
CDKN2A/B
Number of risk alleles Contols (%) Cases (%) OR (95% CI)
0-1 33 (0.52) 8 (0.19) 0.45 (0.21-0.99)
2 150 (2.38) 32 (0.78) 0.4 (0.27-0.59)
3 483 (7.67) 184 (4.48) 0.71 (0.59-0.86)
4 1016 (16.13) 489 (11.9) 0.9 (0.78-1.03)
5 1542 (24.48) 825 (20.08) 1.0  (0.89-1.13) Reference
6 1520 (24.13) 1010 (24.59) 1.24 (1.11-1.39)
7 954 (15.15) 902 (21.96) 1.77 (1.56-2)
8 417 (6.62) 434 (10.56) 1.95 (1.66-2.28)
9 155 (2.46) 174 (4.24) 2.1 (1.66-2.65)
10+ 29 (0.46) 50 (1.22) 3.22 (2.02-5.13)
Total 6299 (100) 4108 (100) 1.24 (1.21-1.28) per allele
P trend = 1.30 x 10
-61
Supplementary Table 5: Odds ratios corresponding to increasing numbers of risk alleles 
in rs4295627 (CCDC26 ), rs498872 (PHLDB1 ), rs497756 (CDKN2A, CDKN2B ), rs2736100 
(TERT ), rs6010620 (RTEL1 ) and rs7124728 (11q13.4). The median number of risk alleles, 5, 
is used as the reference group for the odds ratios.
Region Gene nsSNP Change
5p15.33; rs2736100 TERT D' v rs2736100 r2 v rs2736100
rs35719940 T1062A na na
rs34062885 R948S na na
rs34094720 Y412H na na
rs11952056 T191S na na
SLC8A1 rs5557 V692E na na
9p21.3; rs4977756 CDKN2A D' v rs4977756 r2 v rs4977756
rs45476696 S153G na na
rs3731249 T148A low MAF low MAF
rs6413464 S127A na na
rs34170727 C124R na na
rs6413463 Q123H na na
rs35741010 T102A na na
rs34886500 W99R na na
rs11552822 Y84D na na
rs34968276 Q83H na na
rs11552823 L81P na na
rs36204594 V60A na na
rs36204273 Q58R na na
11q23.3; rs498872 PHLDB1 D' v rs498872 r2 v rs498872
rs35842472 S347T na na
rs35219502 I477T na na
rs11216935 F687L na na
rs2298484 H868A na na
rs12787512 C985S na na
rs497554 W1192R na na
D' v rs498872 r2 v rs498872
TREH rs6589669 S578* na na
rs6589670 A561P na na
rs6589671 A558P low MAF low MAF
rs2276064 W486R low MAF low MAF
rs11827611 H449Y na na
rs2276065 A389T na na
rs34978247 R140K na na
20q13.33; rs6010620 RTEL1 D' v rs6010620 r2 v rs6010620
rs3848668 S124N 1 0.054
rs16983886 N659K na na
rs16983889 I660M na na
rs35640778 Q684R na na
rs12480603 D870E na na
rs6089959 S951G na na
rs3208008 C1042Q na na
ARFRP1 rs35037612 E135K na na
rs35892492 K105E na na
rs11547196 C74W na na
ZGPAT rs1291212 R61S 0.758 0.031
rs6089764 L105P na na
rs17855481 R413G na na
LIME1 rs1151625 L211P 0.758 0.031
Supplementary Table 6: Correlations between the SNPs and nsSNPs mapping with
genes.
i

in nearby
(a) (b)
(c) (d)
Supplementary Figure 1: Identification of individuals in the GWA scan 
of non-European ancestry. The first two principal components of the 
analysis were plotted. HapMap CEU individuals are plotted in red; 
CHB+JPT are plotted in blue; YRI individuals are plotted in black; 
individuals in the GWA-UK and GWA-US are plotted in grey.  GWA-US 
controls are plotted in (a), cases in (b); GWA-UK controls are plotted in (c) 
and cases in (d).
(a) (b)
Supplementary Figure 2: Quantile-quantile (Q-Q) plot of Cochran-Armitage test for trend for the two 
GWA studies. Results from UK-GWA are plotted in (a) and those from the US-GWA in (b). The black line 
represents the null hypothesis of no true association. 
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Supplementary Figure 3:  Regional plots of the 6 confirmed associations (a-f). For 
each of the regions: (a) 8q24.21; (b) 5p15.33; (c) 9p21.3; (d) 20q13.33; (e) 11q23.3; 
and (f) 11q13.4 the upper panel shows single marker association statistics (as –log10 
values) from the GWA-studies in blue and for the combined analysis including the 
replication series in red as a function of genomic position (NCBI build 36.1). Also shown 
are the relative positions of genes mapping to each region of association. Exons of 
genes have been redrawn to show the relative positions in the gene, therefore maps 
are not to physical scale. In the lower panel are the estimated statistics of the square of 
the correlation coefficient (r2), derived from HapMap. The values indicate the LD 
relationship between each pair of SNPs; the darker the shading, the greater extent of 
LD. 
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Supplementary Figure 4: Imputation of 8q24.21 SNPs. In total, 894 HapMap SNPs were successfully imputed in the 
interval between 130,051,729 and 131,225,253bps using available SNP genotype data from GWA scans (225 SNPs). 
Imputed data integrity was verified where possible, by crosschecking the concordance of imputed genotypes with that 
of available Illumina SNP genotype data. Directly genotyped SNPs are denoted in blue, those imputed are shown in 
green. 


Supplementary Figure 5: 5p15.33 (TERT), 8q24.21 (CCDC26), 9p21 (CDKN2A, 
CDKN2B), 11q23.3 (PHLDB1) and 20q13.33 (RTEL1, ARFRP1, STMN3, 
SLC2A4RG, ZGPAT) copy number variation (CNV) and mRNA expression in 
glioma. Plots show mRNA expression stratified by CNV status based on analysis 
of 188 glioblastoma multiforme (GBM) tumors. Expression data was derived from 
the MSKCC Cancer Genomics Data Portal (http://cbio.mskcc.org/cancergenomics-
dataportal/). MSKCC expression data was generated by combining GBM 
expression data from the The Cancer Genome Atlas. The bioconductor module 
CGHcall was used to determine CNV status from Agilent human genome CGH 
microarray data taken from TCGA data portal.  It should be noted that rates of 
amplification and deletion for a set of randomly selected probes are 9.9% and 
13.4% respectively in the tumors. Differences in the distribution of expression by 
SNP genotype were compared using a Wilcoxon-type test. 
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Supplementary Figure 6: Relationship between (a) lymphocyte and (b) normal cortical mRNA expression levels of 
PHLDB1 and rs17748 genotype, CDKN2A/CDKN2B and rs10965224/rs564398/rs1063192/rs2157719/rs1412829/rs49777656 
genotype, ARFRP1/STMN3/SLC2A4RG/TNFRSF6B and rs2297441/rs2738758/rs2297440/rs6010620 genotype and TERT 
and rs2736100 genotype. Expression of PHLDB1, CDKN2A, CDKN2B, ARFRP1, STMN3, SLC2A4RG and TNFRSF6B in 
lymphocytes based on expression data from analysis of 90 Epstein-Barr virus–transformed lymphoblastoid cell lines using Sentrix 
Human-6 Expression BeadChip (Illumina, San Diego, USA)24,25. Expression of PHLDB1, CDKN2A, CDKN2B, ARFRP1, STMN3, 
SLC2A4RG and TNFRSF6B in normal human cortex based on expression data from analysis of 193 normal human brain samples 
using Affymetrix GeneChip Human Mapping 500K Arrays and Illumina HumanRefseq-8 Expression BeadChip platforms26. 
Expression and/or genotype information was not available for every sample and thus the total number of samples may be <193.  
Where SNPs genotyped in our study were not typed HAPMAP data was used to identify correlated SNPs in high LD (r2>0.8).  The 
number of samples with each genotype is given for each plot. Combining the lowest frequency homozygote with the heterozygote 
and re-performing the statistical test produced no further significant results. Differences in the distribution of expression by SNP 
genotype were compared using a Wilcoxon-type test for trend.
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